+

WO2005058950A3 - Procedes pour generer une immunite a un antigene - Google Patents

Procedes pour generer une immunite a un antigene Download PDF

Info

Publication number
WO2005058950A3
WO2005058950A3 PCT/US2004/041690 US2004041690W WO2005058950A3 WO 2005058950 A3 WO2005058950 A3 WO 2005058950A3 US 2004041690 W US2004041690 W US 2004041690W WO 2005058950 A3 WO2005058950 A3 WO 2005058950A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigen
fusion protein
immune response
methods
ligand
Prior art date
Application number
PCT/US2004/041690
Other languages
English (en)
Other versions
WO2005058950A2 (fr
Inventor
Albert Deisseroth
Yucheng Tang
Wei-Wei Zhang
Xiang-Ming Fang
Original Assignee
Sidney Kimmel Cancer Ct
Albert Deisseroth
Yucheng Tang
Wei-Wei Zhang
Xiang-Ming Fang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sidney Kimmel Cancer Ct, Albert Deisseroth, Yucheng Tang, Wei-Wei Zhang, Xiang-Ming Fang filed Critical Sidney Kimmel Cancer Ct
Priority to EP04813939A priority Critical patent/EP1720905A2/fr
Priority to CA002548347A priority patent/CA2548347A1/fr
Priority to JP2006544078A priority patent/JP2008504219A/ja
Publication of WO2005058950A2 publication Critical patent/WO2005058950A2/fr
Publication of WO2005058950A3 publication Critical patent/WO2005058950A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des procédés pour générer une réponse immunitaire à un antigène. Ces procédés consistent à mettre en condition un individu en administrant un vecteur d'expression qui code l'antigène. Ce vecteur comprend une unité de transcription qui code une protéine de fusion pouvant être sécrétée, qui contient un antigène et un ligand CD40. L'administration d'une protéine de fusion contenant l'antigène et un ligand CD40 est utilisée pour améliorer la réponse immunitaire au-delà de celle obtenue par l'administration du vecteur seul. Les procédés selon cette invention peuvent être utilisés pour générer une réponse immunitaire contre un cancer exprimant un antigène tumoral, tel qu'un antigène tumoral de mucine ou de papillomavirus humain, et pour générer une réponse immunitaire contre un agent infectieux. La présente invention concerne également un procédé pour produire simultanément le vecteur d'expression et la protéine de fusion.
PCT/US2004/041690 2003-12-11 2004-12-10 Procedes pour generer une immunite a un antigene WO2005058950A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04813939A EP1720905A2 (fr) 2003-12-11 2004-12-10 Procedes pour generer une immunite a un antigene
CA002548347A CA2548347A1 (fr) 2003-12-11 2004-12-10 Procedes pour generer une immunite a un antigene
JP2006544078A JP2008504219A (ja) 2003-12-11 2004-12-10 抗原に対する免疫を生じさせる方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59201603P 2003-12-11 2003-12-11
US60/592,016 2004-07-29

Publications (2)

Publication Number Publication Date
WO2005058950A2 WO2005058950A2 (fr) 2005-06-30
WO2005058950A3 true WO2005058950A3 (fr) 2006-03-02

Family

ID=34700248

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/041690 WO2005058950A2 (fr) 2003-12-11 2004-12-10 Procedes pour generer une immunite a un antigene

Country Status (3)

Country Link
EP (1) EP1720905A2 (fr)
CA (1) CA2548347A1 (fr)
WO (1) WO2005058950A2 (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006061414A1 (fr) * 2004-12-09 2006-06-15 Ingenium Pharmaceuticals Ag Procedes et agents utilises dans le traitement d'etats caracterises par l'hyperproduction/ hypersecretion de mucus
EP1951862B1 (fr) 2005-11-07 2013-07-24 MicroVAX, LLC Vaccin à base de protéine de fusion portant un ligand cd40
WO2008036675A2 (fr) 2006-09-18 2008-03-27 The Board Of Trustees Of The University Of Arkansas Compositions et procédés pour améliorer des réponses immunes
US10174100B1 (en) * 2006-11-06 2019-01-08 Microvax, Llc Multivalent DNA composition for Yersinia pestis
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
BRPI0818736A2 (pt) 2007-10-30 2017-06-13 Univ Arkansas composições e métodos para intensificar imunorrepostas à bactéria flagelada
DK2214701T3 (en) 2007-11-01 2016-12-12 Univ Arkansas CONFIGURATIONS AND METHODS FOR IMPROVING THE IMMUNE RESPONSES TO Eimeria
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
KR101881611B1 (ko) 2010-06-09 2018-07-25 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 캄필로박터 감염을 감소시키기 위한 백신 및 방법
WO2014031178A1 (fr) 2012-08-24 2014-02-27 Etubics Corporation Vecteur adénoviral à réplication déficiente, utile en vaccination
CA2900644C (fr) 2013-02-14 2023-03-14 The Board Of Trustees Of The University Of Arkansas Compositions et procedes pour renforcer des reponses immunitaires vis-a-vis d'eimeria ou limiter une infection par eimeria
SG11201507421XA (en) 2013-03-15 2015-10-29 Univ Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
CN104345152B (zh) * 2013-08-08 2016-09-21 中国人民解放军第二军医大学东方肝胆外科医院 MUC15与p-AKT在制备肝癌预后评估试剂盒中的应用
KR20170102002A (ko) 2015-01-09 2017-09-06 이투빅스 코포레이션 에볼라 바이러스 백신접종을 위한 방법 및 조성물
EP3242940B1 (fr) 2015-01-09 2023-03-29 Etubics Corporation Méthodes et compositions d'immunothérapie combinée
AU2016215175B2 (en) * 2015-02-06 2021-09-16 Heat Biologics, Inc. Vector co-expressing vaccine and costimulatory molecules
WO2016172249A1 (fr) 2015-04-20 2016-10-27 Etubics Corporation Méthodes et compositions d'immunothérapie combinée
AR108688A1 (es) 2016-05-03 2018-09-19 Univ Arkansas Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso
CA3040123A1 (fr) 2016-10-11 2018-04-19 University Of Miami Vecteurs et cellules de vaccin pour immunite contre le virus zika
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056602A2 (fr) * 2000-02-02 2001-08-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adjuvant du ligand cd40 destine au virus respiratoire syncytial

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056602A2 (fr) * 2000-02-02 2001-08-09 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adjuvant du ligand cd40 destine au virus respiratoire syncytial

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DAKAPPAGARI N K ET AL: "A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 170, no. 8, 15 April 2003 (2003-04-15), pages 4242 - 4253, XP002290185, ISSN: 0022-1767 *
DIEHL L ET AL: "CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy", NATURE MEDICINE, NATURE PUBLISHING, CO, US, vol. 5, no. 7, July 1999 (1999-07-01), pages 774 - 779, XP002153727, ISSN: 1078-8956 *
MOINGEON P: "Cancer vaccines", VACCINE, BUTTERWORTH SCIENTIFIC. GUILDFORD, GB, vol. 19, no. 11-12, 8 December 2001 (2001-12-08), pages 1305 - 1326, XP004313943, ISSN: 0264-410X *
TANG YUCHENG ET AL: "Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens.", BLOOD. 1 NOV 2004, vol. 104, no. 9, 1 November 2004 (2004-11-01), pages 2704 - 2713, XP009048261, ISSN: 0006-4971 *
XIANG R ET AL: "A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancer in carcinoembryonic antigen-transgenic mice", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 167, no. 8, 15 October 2001 (2001-10-15), pages 4560 - 4565, XP002247590, ISSN: 0022-1767 *
ZHANG L ET AL: "An adenoviral vector cancer vaccine that delivers a tumor-asociated antigen/CD40 ligand fusion protein to dendritic cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 100, no. 25, 9 December 2003 (2003-12-09), pages 15101 - 15106, XP002978256, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
CA2548347A1 (fr) 2005-06-30
EP1720905A2 (fr) 2006-11-15
WO2005058950A2 (fr) 2005-06-30

Similar Documents

Publication Publication Date Title
WO2005058950A3 (fr) Procedes pour generer une immunite a un antigene
WO2006130525A3 (fr) Procedes d'immunotherapie de cancer
WO2004044176A3 (fr) Vaccin a vecteur adenoviral
DE69834671D1 (de) Immunantwort gegen HPV Antigene hervorgerufen von Zusammensetzungen die ein HPV Antigen und ein Stressprotein enthalten oder einem Expressionsvektor fähig zur Expression dieser Proteine
EA023888B1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
IL214460A0 (en) Malaria prime/boost vaccines
WO2004084939A8 (fr) Conjugues porteurs de peptides du vih
WO2002074795A3 (fr) Complexes de proteines oligomeres recombinantes a potentiel immunogene ameliore
WO2002069907A8 (fr) Preparations anti-neovaisseaux destinees au traitement anticancereux
WO2005051991A3 (fr) Vaccin d'antigene de mucine
WO2001056602A3 (fr) Adjuvant du ligand cd40 destine au virus respiratoire syncytial
AU1013701A (en) Modified gp100 and uses thereof
WO2012047679A3 (fr) Produits de synthèse d'antigène consensus et vaccins fabriqués à partir de ceux-ci, et procédés d'utilisation de ceux-ci pour traiter le paludisme
CY1109257T1 (el) Χιμαιρικες πρωτεϊνες l1 του ιου 16 ανθρωπινων θηλωματων που περιλαμβανουν l2 πεπτιδιο, ομοιαζοντα με ιο σωματιδια που παρασκευαζονται απο αυτες και μεθοδος παρασκευης των σωματιδιων
JP2011519869A5 (fr)
WO2003017032A3 (fr) Methodes informatisees d'identification de molecules
WO2003011331A3 (fr) Matieres et techniques relatives a des strategies de vaccination ameliorees
WO2006073431A3 (fr) Genes du virus de la fievre aphteuse exprimant des recombines avipox
WO2007046839A3 (fr) Nouveaux vaccins a base de virus vivant
WO2003062374A3 (fr) Genes de synthese de proteines de la malaria et leurs procedes d'utilisation
HUP0400703A2 (hu) Csökkentett immunogenitású módosított eritropoietin (EPO)
WO2003051454A3 (fr) Procedes d'immunisation assistee par particules reposant sur l'utilisation d'un champ electrique pulse
WO2003093298A3 (fr) Peptides immunogenes
HK1074643A1 (en) Recombinant mva capable of expressing structural hcv antigens
WO2000052045A3 (fr) Peptides immunogenes derives de mage-3 presentes par le complexe majeur d'histocompatibilte (mch) de categorie ii et utilisations associees

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2548347

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004813939

Country of ref document: EP

Ref document number: 2006544078

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2004813939

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载